Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice

Neurotherapeutics

Volumn 9, Issue 4, 2012, Pages 814-826

  Mancuso, Renzo ^a,b   Oliván, Sara ^c   Rando, Amaya ^c   Casas, Caty ^a,b   Osta, Rosario ^c   Navarro, Xavier ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

Amyotrophic lateral sclerosis; Motoneuron disease; PRE 084; Sigma 1 receptor; SOD1G93A mice

Indexed keywords

1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; COPPER ZINC SUPEROXIDE DISMUTASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN KINASE C;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; ELECTROPHYSIOLOGY; ENZYME PHOSPHORYLATION; FEMALE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; MOTONEURON; MOTOR PERFORMANCE; MOUSE; MUSCLE ACTION POTENTIAL; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; WESTERN BLOTTING;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BLOTTING, WESTERN; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, TRANSGENIC; MORPHOLINES; MOTOR ACTIVITY; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; RECEPTORS, SIGMA; SUPEROXIDE DISMUTASE;

EID: 84868021206     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0140-y     Document Type: Article

References (51)

1. Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis 2009; 4: 3.
2. Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 364: 362.
3. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1995; 92: 689-693.
4. Bosco DA, Morfini G, Karabacak NM, et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci 2010; 13: 1396-1403.
5. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nature Rev Neurosci 2006; 7: 710-723.
6. Alonso G, Phan V-L, Guillemain I, et al. Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system. Neuroscience 2000; 97: 155-170.
7. Hayashi T, Su T-P. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007; 131: 596-610.
8. Gekker G, Hu S, Sheng WS, Rock RB, Lokensgard JR, Peterson PK. Cocaine-induced HIV-1 expression in microglia involves sigma-1 receptors and transforming growth factor-beta1. Int Immunopharmacol 2006; 6: 1029-1033.
9. Palacios G, Muro A, Vela JM, et al. Immunohistochemical localization of the sigma1-receptor in oligodendrocytes in the rat central nervous system. Brain Res 2003; 961: 92-99.
10. Penas C, Pascual-Font A, Mancuso R, Forés J, Casas C, Navarro X. Sigma receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury. J Neurotrauma 2011; 28: 831-840.
11. Morin-Surun MP, Collin T, Denavit-Saubié M, Baulieu EE, Monnet FP. Intracellular sigma1 receptor modulates phospholipase C and protein kinase C activities in the brainstem. Proc Natl Acad Sci USA 1999; 96: 8196-8199.
12. Mavlyutov TA, Ruoho AE. Ligand-dependent localization and intracellular stability of sigma-1 receptors in CHO-K1 cells. J Mol Signal 2007; 2: 8.
13. Hall AA, Herrera Y, Ajmo CT Jr., Cuevas J, Pennypacker KR. Sigma receptors suppress multiple aspects of microglial activation. Glia 2009; 57: 744-754.
14. Zhang X-J, Liu L-L, Jiang S-X, Zhong Y-M, Yang X-L. Activation of the ζ receptor 1 suppresses NMDA responses in rat retinal ganglion cells. Neuroscience 2011; 177: 12-22.
15. Maurice T, Su T-P. The pharmacology of sigma-1 receptors. Pharmacol Therap 2009; 124: 195-206.
16. Aydar E, Palmer CP, Klyachko VA, Jackson MB. The sigma receptor as a ligand-regulated auxiliary potassium channel subunit. Neuron 2002; 34: 399-410.
17. Tuerxun T, Numakawa T, Adachi N, et al. SA4503, a sigma-1 receptor agonist, prevents cultured cortical neurons from oxidative stress-induced cell death via suppression of MAPK pathway activation and glutamate receptor expression. Neurosci Lett 2010; 469: 303-308.
18. Guzmán-Lenis M-S, Navarro X, Casas C. Selective sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) promotes neuroprotection and neurite elongation through protein kinase C (PKC) signaling on motoneurons. Neuroscience 2009; 162: 31-38.
19. Allahtavakoli M, Jarrott B. Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats. Brain Res Bull 2011; 85: 219-224.
20. Ajmo CT, Vernon DOL, Collier L, Pennypacker KR, Cuevas J. Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats. Curr Neurovasc Res 2006; 3: 89-98.
21. Luty AA, Kwok JBJ, Dobson-Stone C, et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 2010; 68: 639-649.
22. Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann Neurol 2011; 70: 913-919.
23. Mancuso R, Santos-Nogueira E, Osta R, Navarro X. Electrophysiological analysis of a murine model of motoneuron disease. Clin Neurophysiol 2011; 122: 1660-1670.
24. Valero-Cabré A, Navarro X. H reflex restitution and facilitation after different types of peripheral nerve injury and repair. Brain Res 2001; 919: 302-312.
25. Mancuso R, Oliván S, Osta R, Navarro X. Evolution of gait abnormalities in SOD1(G93A) transgenic mice. Brain Res 2011; 1406: 65-73.
26. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946; 94: 239-247.
27. Moreno-Igoa M, Calvo AC, Penas C, et al. Fragment C of tetanus toxin, more than a carrier. Novel perspectives in non-viral ALS gene therapy. J Mol Med 2010; 88: 297-308.
28. Penas C, Casas C, Robert I, Forés J, Navarro X. Cytoskeletal and activity-related changes in spinal motoneurons after root avulsion. J Neurotrauma 2009; 26: 763-779.
29. Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004; 185: 232-240.
30. Mohajeri MH, Figlewicz DA, Bohn MC. Selective loss of alpha motoneurons innervating the medial gastrocnemius muscle in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 1998; 150: 329-336.
31. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH. TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci USA 2009; 106: 18809-18814.
32. McHanwell S, Biscoe TJ. The localization of motoneurons supplying the hindlimb muscles of the mouse. Philos Trans R Soc Lond B Biol Sci 1981; 293: 477-508.
33. Diaz-Amarilla P, Olivera-Bravo S, Trias E, et al. Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2011; 108: 18126-18131.
34. Yamanaka K, Boillee S, Roberts EA, et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci USA 2008; 105: 7594-7599.
35. Sanagi T, Yuasa S, Nakamura Y, et al. Appearance of phagocytic microglia adjacent to motoneurons in spinal cord tissue from a presymptomatic transgenic rat model of amyotrophic lateral sclerosis. J Neurosci Res 2010; 88: 2736-2746.
36. Haidet-Phillips AM, Hester ME, Miranda CJ, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 2011; 29: 824-828.
37. Azzouz M, Leclerc N, Gurney M, Warter JM, Poindron P, Borg J. Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis. Muscle Nerve 1997; 20: 45-51.
38. Raoul C, Abbas-Terki T, Bensadoun J-C, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005; 11: 423-428.
39. Turner B, Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008; 85: 94-134.
40. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157.
41. Lockhart BP, Soulard P, Benicourt C, Privat A, Junien JL. Distinct neuroprotective profiles for sigma ligands against N-methyl-D-aspartate (NMDA), and hypoxia-mediated neurotoxicity in neuronal culture toxicity studies. Brain Res 1995; 675: 110-120.
42. Katnik C, Guerrero WR, Pennypacker KR, Herrera Y, Cuevas J. Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia. J Pharmacol Exp Ther 2006; 319: 1355-1365.
43. Antonini V, Marrazzo A, Kleiner G, et al. Anti-amnesic and neuroprotective actions of the sigma-1 receptor agonist (-)-MR22 in rats with selective cholinergic lesion and amyloid infusion. J Alzheimers Dis 2011; 24: 569-586.
44. Mancuso R, Oliván S, Mancera P, et al. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012; 13: 302-310.
45. Grosskreutz J, van Den Bosch L, Keller BU. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium 2010; 47: 165-174.
46. van Den Bosch L, van Damme P, Bogaert E, Robberecht W. The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochimica Biophysica Acta 2006; 1762: 1068-1082.
47. Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994; 36: 846-858.
48. Texidó L, Hernández S, Martín-Satué M, et al. Sera from amyotrophic lateral sclerosis patients induce the non-canonical activation of NMDA receptors "in vitro." Neurochem Int 2011; 59: 954-964.
49. Sunico CR, Domínguez G, García-Verdugo JM, Osta R, Montero F, Moreno-López B. Reduction in the motoneuron inhibitory/excitatory synaptic ratio in an early-symptomatic mouse model of amyotrophic lateral sclerosis. Brain Pathol 2011; 21: 1-15.
50. Henkel JS, Beers DR, Zhao W, Appel SH. Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol 2009; 4: 389-398.
51. Sargsyan SA, Blackburn DJ, Barber SC, et al. A comparison of in vitro properties of resting SOD1 transgenic microglia reveals evidence of reduced neuroprotective function. BMC Neuroscience 2011; 12: 91.